HIV Infections Clinical Trial
Official title:
Family-Based HIV Prevention for Latinos
| Verified date | June 2012 |
| Source | Rhode Island Hospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Institutional Review Board |
| Study type | Interventional |
The proposed project will develop and test an HIV prevention intervention for Latino
families. This study will:
1. Conduct a pilot "run-through" of an adapted family-based intervention with three
cohorts (about 24 families) to determine the feasibility, acceptability, and
appropriateness for the target population.
2. Revise the family-based HIV prevention intervention based on the results of the pilot
"run-through" and structured exit interviews.
3. Recruit and randomize 100 families into the Latino family-based HIV prevention
intervention or a general health promotion condition.
4. Estimate the effect size of the Latino family-based HIV prevention intervention from
assessment of changes in HIV-related sexual behavior and attitudes and parental
monitoring/supervision over 6 months.
Based on a thorough review of the literature, the following is anticipated:
1. The revised intervention will be feasible, acceptable, and appropriate for Latino
families and will be enthusiastically received.
2. The family-based HIV prevention intervention will result in safer adolescent sexual
behavior, greater change with regard to primary outcome measures of behavior (recent
sexual activity, the number of unprotected sex acts, proportion of condom use, and
intentions to use condoms), safer HIV-related attitudes, improved parent-child
communication skills, and greater parental monitoring than the Latino families in the
general health promotion condition.
| Status | Completed |
| Enrollment | 80 |
| Est. completion date | September 2010 |
| Est. primary completion date | September 2010 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 13 Years to 18 Years |
| Eligibility |
Inclusion Criteria: - Adolescent must be English-speaking and can converse in Spanish with parent - Parent must be Spanish-speaking - Adolescent and parent must be living together for at least 3 months prior to workshop - Both parent and adolescent self-identify as being of Hispanic/Latino origin Exclusion Criteria: - Adolescent HIV positive - Adolescent pregnant or intending to get pregnant - Active psychosis |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
| Country | Name | City | State |
|---|---|---|---|
| United States | Rhode Island Hospital | Providence | Rhode Island |
| Lead Sponsor | Collaborator |
|---|---|
| Rhode Island Hospital |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number (#) of unprotected sex acts | baseline, 3, and 6 months | No | |
| Secondary | parent-child communication | baseline, 3, and 6 months | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |